Arbutus Biopharma Corp Stock Buy Hold or Sell Recommendation
| ABUS Stock | USD 3.50 0.23 7.03% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Arbutus Biopharma Corp is 'Strong Sell'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell Arbutus Biopharma Corp given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for Arbutus Biopharma Corp, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Arbutus Biopharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Arbutus and provide practical buy, sell, or hold advice based on investors' constraints. Arbutus Biopharma Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.
Arbutus |
Execute Arbutus Biopharma Buy or Sell Advice
The Arbutus recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Arbutus Biopharma Corp. Macroaxis does not own or have any residual interests in Arbutus Biopharma Corp or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Arbutus Biopharma's advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Weak | Details | |
Volatility | Slightly risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Arbutus Biopharma Trading Alerts and Improvement Suggestions
| Arbutus Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 6.17 M. Net Loss for the year was (69.92 M) with loss before overhead, payroll, taxes, and interest of (56.05 M). | |
| Arbutus Biopharma Corp currently holds about 150.2 M in cash with (64.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.0. | |
| Arbutus Biopharma has a very weak financial position based on the latest SEC disclosures | |
| Roughly 55.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments |
Arbutus Biopharma Returns Distribution Density
The distribution of Arbutus Biopharma's historical returns is an attempt to chart the uncertainty of Arbutus Biopharma's future price movements. The chart of the probability distribution of Arbutus Biopharma daily returns describes the distribution of returns around its average expected value. We use Arbutus Biopharma Corp price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Arbutus Biopharma returns is essential to provide solid investment advice for Arbutus Biopharma.
| Mean Return | 0.06 |
| Value At Risk | -4.39 |
| Potential Upside | 4.08 |
| Standard Deviation | 2.47 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Arbutus Biopharma historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Arbutus Stock Institutional Investors
The Arbutus Biopharma's institutional investors refer to entities that pool money to purchase Arbutus Biopharma's securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | |||
| Advisor Group Holdings, Inc. | 2024-12-31 | 1.4 M | |
| Northern Trust Corp | 2024-12-31 | 1.3 M | |
| Fourworld Capital Management Llc | 2024-12-31 | 1.2 M | |
| Charles Schwab Investment Management Inc | 2024-12-31 | 1.2 M | |
| Hudson Bay Capital Management Lp | 2024-12-31 | 1.1 M | |
| Woodline Partners Lp | 2024-12-31 | 971.6 K | |
| Jpmorgan Chase & Co | 2024-12-31 | 896.3 K | |
| Saba Capital Management, Lp | 2024-12-31 | 888 K | |
| Corbin Capital Partners Lp | 2024-12-31 | 682.5 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 22.6 M | |
| Whitefort Capital Management, Lp. | 2024-12-31 | 13.2 M |
Arbutus Biopharma Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 20.5M | 57.0M | (78.5M) | (4.5M) | 10.0M | 10.5M | |
| Free Cash Flow | (51.7M) | (68.3M) | (35.9M) | (86.9M) | (65.0M) | (61.8M) | |
| Depreciation | 2.0M | 1.8M | 1.4M | 1.4M | 1.4M | 1.4M | |
| Capital Expenditures | 229K | 809K | 512K | 1.0M | 182K | 172.9K | |
| Net Income | (63.7M) | (76.2M) | (69.5M) | (72.8M) | (69.9M) | (73.4M) | |
| End Period Cash Flow | 52.3M | 109.3M | 30.8M | 26.3M | 36.3M | 39.9M | |
| Other Non Cash Items | 9.3M | 7.8M | (3.8M) | (5.6M) | 501K | 476.0K | |
| Investments | (14.7M) | (11.9M) | (74.4M) | 41.2M | 22.9M | 24.1M | |
| Dividends Paid | 10.1M | 11.1M | 12.1M | 12.1M | 14.0M | 14.7M | |
| Change To Netincome | 58.6M | 3.2M | 2.2M | 1.8M | 2.0M | 1.9M | |
| Change Receivables | 227K | (108K) | 413K | (453K) | (407.7K) | (387.3K) |
Arbutus Biopharma Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Arbutus Biopharma or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Arbutus Biopharma's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Arbutus stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.05 | |
β | Beta against Dow Jones | -0.05 | |
σ | Overall volatility | 2.57 | |
Ir | Information ratio | 0.04 |
Arbutus Biopharma Volatility Alert
Arbutus Biopharma Corp currently demonstrates below-average downside deviation. It has Information Ratio of 0.04 and Jensen Alpha of 0.05. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Arbutus Biopharma's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Arbutus Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Arbutus Biopharma Fundamentals Vs Peers
Comparing Arbutus Biopharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Arbutus Biopharma's direct or indirect competition across all of the common fundamentals between Arbutus Biopharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Arbutus Biopharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Arbutus Biopharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Arbutus Biopharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Arbutus Biopharma to competition |
| Fundamentals | Arbutus Biopharma | Peer Average |
| Return On Equity | -0.68 | -0.31 |
| Return On Asset | -0.33 | -0.14 |
| Operating Margin | (13.05) % | (5.51) % |
| Current Valuation | 493.29 M | 16.62 B |
| Shares Outstanding | 189.49 M | 571.82 M |
| Shares Owned By Insiders | 22.25 % | 10.09 % |
| Shares Owned By Institutions | 55.33 % | 39.21 % |
| Number Of Shares Shorted | 7.21 M | 4.71 M |
| Price To Earning | (1.16) X | 28.72 X |
| Price To Book | 5.80 X | 9.51 X |
| Price To Sales | 91.91 X | 11.42 X |
| Revenue | 6.17 M | 9.43 B |
| Gross Profit | (56.05 M) | 27.38 B |
| EBITDA | (77.14 M) | 3.9 B |
| Net Income | (69.92 M) | 570.98 M |
| Cash And Equivalents | 150.2 M | 2.7 B |
| Cash Per Share | 1.00 X | 5.01 X |
| Total Debt | 34.34 M | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 5.29 X | 2.16 X |
| Book Value Per Share | 0.56 X | 1.93 K |
| Cash Flow From Operations | (64.85 M) | 971.22 M |
| Short Ratio | 8.76 X | 4.00 X |
| Earnings Per Share | (0.43) X | 3.12 X |
| Target Price | 5.23 | |
| Beta | 1.93 | -0.15 |
| Market Capitalization | 619.64 M | 19.03 B |
| Total Asset | 131.71 M | 29.47 B |
| Retained Earnings | (1.35 B) | 9.33 B |
| Working Capital | 111.7 M | 1.48 B |
| Current Asset | 183.88 M | 9.34 B |
| Current Liabilities | 10.58 M | 7.9 B |
| Net Asset | 131.71 M |
Note: Acquisition by Androski Lindsay of 310422 shares of Arbutus Biopharma at 3.2 subject to Rule 16b-3 [view details]
Arbutus Biopharma Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Arbutus . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Arbutus Biopharma Buy or Sell Advice
When is the right time to buy or sell Arbutus Biopharma Corp? Buying financial instruments such as Arbutus Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Arbutus Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Healthcare Thematic Idea Now
Healthcare
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Healthcare theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Healthcare Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Arbutus Stock Analysis
When running Arbutus Biopharma's price analysis, check to measure Arbutus Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arbutus Biopharma is operating at the current time. Most of Arbutus Biopharma's value examination focuses on studying past and present price action to predict the probability of Arbutus Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arbutus Biopharma's price. Additionally, you may evaluate how the addition of Arbutus Biopharma to your portfolios can decrease your overall portfolio volatility.